Evidence map›Paper›PMID 39791428›Full record

ArticleJournal of the American Heart Association2025

Targeting P21-Activated Kinase 2 as a Novel Therapeutic Approach to Mitigate Endoplasmic Reticulum Stress in Heart Failure With Preserved Ejection Fraction.

Hongyuan Zhang, Honglin Xu, Fangchao Zhou, Tayyiba Azam, Sultan Samman, Pablo Binder, Binh Nguyen, Elizabeth J Cartwright, Oliver J Müller, Susanne S Hille and 5 more

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hongyuan ZhangDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-1012-4141
Honglin XuDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.
Fangchao ZhouDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.
Tayyiba AzamDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-6099-0494
Sultan SammanDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-6408-6996
Pablo BinderDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-5927-5928
Binh NguyenDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.
Elizabeth J CartwrightDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-6836-7795
Oliver J MüllerDepartment of Internal Medicine III University of Kiel Kiel Germany.ORCID 0000-0001-8223-2638
Susanne S HilleDepartment of Internal Medicine III University of Kiel Kiel Germany.ORCID 0000-0002-9809-4636
Fay PuFurness General Hospital Dalton Lane Barrow-In-Furness UK.
Darren GreenUniversity of Manchester Manchester UK.ORCID 0000-0002-9370-8176
Yanrong LiuDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.
Min ZiDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0002-4183-1818
Xin WangDivision of Cardiovascular Science, Faculty of Biology, Medicine and Health The University of Manchester Manchester UK.ORCID 0000-0001-7555-5244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart failure with preserved ejection fraction (HFpEF) is linked to prolonged endoplasmic reticulum (ER) stress. P21-activated kinase 2 (Pak2) facilitates a protective ER stress response. This study explores the mechanism and role of Pak2 in HFpEF pathology. METHODS AND

resultsThe HFpEF mouse model was established using a high-fat diet combined with the nitric oxide synthase inhibitor Nω-Nitro-l-arginine methyl ester (high-fat diet+Nω-Nitro-l-arginine methyl ester). The model exhibited the typical characteristics of HFpEF (cardiac hypertrophy, diastolic dysfunction with preserved systolic function, and lung edema) as determined by echocardiography and hemodynamic analysis. Terminal deoxynucleotidyl transferase dUTP nick end labeling and dihydroethidium staining results showed that cell death and reactive oxygen species generation were higher in the high-fat diet+Nω-Nitro-l-arginine methyl ester-treated group. Transmission electron microscopy revealed disruption of the ER subcellular structures in the HFpEF mouse model, while western blot analysis confirmed reduced Pak2 phosphorylation and impaired inositol-requiring enzyme 1/X-box binding protein 1 splicing ER stress response signaling. Furthermore, H9c2 cells subjected to the palmitic acid-mediated metabolic stress developed temporal changes in unfolded protein response proteins and Pak2 activity. The inositol requiring enzyme 1/X-box binding protein 1 splicing branch of unfolded protein response was impaired earlier than other branches. Overexpression of Pak2 by adenovirus in H9c2 cells sustained the activation of inositol requiring enzyme 1/X-box binding protein 1 splicing. Pak2 deficiency in the mouse heart accelerated the HFpEF progression, and this phenomenon occurred as early as 10 weeks in Pak2 cardiomyocyte-specific knockout mice. Conversely, adeno-associated virus serotype 9-mediated Pak2 overexpression mitigated HFpEF symptoms, underscoring its protective role against HFpEF progression.

conclusionsPak2 prevents HFpEF progression, exerting cardioprotective effects against ER stress. These insights underscore the therapeutic value of Pak2 in HFpEF.

Indexed as

Endoplasmic Reticulum StressHeart FailureMyocytes, Cardiacp21-Activated KinasesStroke VolumeVentricular Function, LeftAnimalsApoptosisDiet, High-FatDisease Models, AnimalMaleMiceMice, Inbred C57BLNG-Nitroarginine Methyl EsterSignal TransductionNG-Nitroarginine Methyl Esterp21-Activated KinasesPak2 protein, mouseendoplasmic reticulum stressheart failure with preserved ejection fractionp21‐activated kinase 2

Identifiers

PMID39791428
PMCPMC12054525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.